$LLY - Eli Lilly positioned as the safest play on personalized peptides and longevity, acquiring biotech companies and reportedly having more NVIDIA AI chips than any pharmaceutical company to develop customized health interventions.
$EQUITIES - Extended longevity requires long-duration assets to match liabilities. Stocks are the only asset class with sufficient duration (30-50 years) to match extended lifespans, fundamentally changing portfolio allocation away from 60/40 models.
$LONGEVITY - Total addressable market for longevity and healthcare wellness is underestimated. Wealthy individuals will allocate significant capital to health as precedents like LeBron James ($2M/year) and Brian Johnson demonstrate the value of longevity investments.
$IRL - Anti-AI trade focused on human connection, nature, and in-person experiences. As AI-generated content becomes abundant and cheap, scarce human interaction becomes more valuable. Psilocybin (DFDV) cited as example, up 100%.
$HIMSS - HIMSS positioned as distribution play for personalized peptides through clinics providing diagnostic testing, blood work, coaching and physician oversight for GLP-1 and peptide therapies.
Bearish:
$ALCOHOL - GLP-1 medications suppress alcohol cravings in addition to food appetite. Declining alcohol consumption driven by health awareness and alternatives like cannabis/psilocybin. French luxury champagne brands already seeing demand weakness.
$RESTAURANTS - Restaurant sector in bear market for years. GLP-1 adoption (65% of patients per one physician's report) suppressing food appetite and reducing dining out. Bars shutting down, theater attendance dropping.
$BONDS - 60/40 portfolio allocation dead for longevity investors. Bonds have insufficient duration and negative real returns in higher-for-longer inflation environment. Fed acknowledging inflation above target makes bond holdings value-destructive.
$SOCIALSECURITY - Social Security system designed when life expectancy was 65-70, now facing insolvency by 2032 as longevity extends. Likely means-testing will cut benefits for wealthy individuals, forcing more equity allocation.
$ANNUITIES - Insurance companies offering lifetime income annuities face existential risk if longevity extends significantly. Actuarial tables not anticipating 50% of people living to 110 could cause companies like MetLife and Allianz to run out of money.